1. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
- Author
-
Carlos Taxonera, María Jesús Fernández‐Aceñero, David Olivares, Marta Calvo, Begoña Casis, Fernando Bermejo, Pilar López Serrano, Marisa Iborra, Francisco Mesonero, Maia Boscá Watts, Cristina Díaz del Arco, Isabel Vera, Sonsoles Olivares, Alicia Algaba, and Cristina Alba
- Subjects
Hepatology ,therapeutic drug monitoring ,Remission Induction ,Gastroenterology ,histologic remission ,Antibodies, Monoclonal ,Colonoscopy ,endoscopic healing ,Cross-Sectional Studies ,Humans ,Pharmacology (medical) ,Colitis, Ulcerative ,golimumab ,pharmacokinetic ,Leukocyte L1 Antigen Complex ,disease clearance ,ulcerative colitis - Abstract
BACKGROUND: Optimal thresholds for golimumab concentrations during maintenance for important outcomes are lacking. AIM: The aim of the study was to investigate the association of golimumab trough concentrations during maintenance with key outcomes, including endoscopic and histologic remission, and long-term event-free persistence with golimumab, in patients with UC. METHODS: This multicentre, cross-sectional study included UC patients on golimumab maintenance recruited either in remission or during a flare. Colonoscopy was scheduled, and study-specific rectocolonic biopsies were taken for blind central histologic reading. Samples for golimumab trough concentrations were collected close to colonoscopy. RESULTS: Fifty-two patients were included. Median golimumab trough concentrations (µg/ml) were significantly higher in patients who had clinical remission (2.01 vs. 0.72, p = 0.047), combined clinical-biochemical remission (PMS =2 + faecal calprotectin
- Published
- 2022